On 24 October 2022, the European Commission granted an Authorisation for the following substance:

1. 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated (4-tert-OPnEO)

Authorisation number REACH/22/38/0 is held by Swords Laboratories Unlimited Company, and approves the industrial use of 4-tert-OPnEO as a surfactant in the purification of the biopharmaceutical drug Orencia, used for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis and adult psoriatic arthritis